Skip to main content

RT @uptoTate: Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https:…

Social Author Name
Dr. Rachel Tate
Tweet Content

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M

×